Clinical Trial Update: Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) [Phase 3]

View source ↗

Summary

A Phase 3 trial of the renin inhibitor aliskiren in Type 2 Diabetes mellitus evaluating cardiovascular and renal outcomes (Core and Extension phases) sponsored …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Tekturna (aliskiren)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease | Phase 3 | Status: TERMINATED | Results posted: 2014-03-18